Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies.

A rationally designed oligomerization inhibitor interacts with early intermediate assemblies of amyloid-beta polypeptide (Abeta) through the aromatic elements and inhibits their assembly into the toxic oligomers that cause Alzheimer's disease by a unique C(alpha)-methylation beta-breakage strategy. The electrostatic potential of the low-energy conformation of the dipeptide inhibitor bound to Abeta is shown.

[1]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[2]  H. Nakanishi,et al.  NMR and CD studies on the interaction of Alzheimer β-amyloid peptide (12–28) with β-cyclodextrin , 2002 .

[3]  A. Gräslund,et al.  Reversible Random Coil to β-Sheet Transition and the Early Stage of Aggregation of the Aβ(12−28) Fragment from the Alzheimer Peptide , 2000 .

[4]  R. Ostrovskaya,et al.  The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model , 2007, Journal of psychopharmacology.

[5]  D. Kirschner,et al.  Structure of core domain of fibril-forming PHF/Tau fragments. , 2006, Biophysical journal.

[6]  Pawel Sikorski,et al.  Molecular basis for amyloid fibril formation and stability. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Amadei,et al.  Molecular dynamics simulation of the aggregation of the core‐recognition motif of the islet amyloid polypeptide in explicit water , 2005, Proteins.

[8]  A. Cavalli,et al.  The role of aromaticity, exposed surface, and dipole moment in determining protein aggregation rates , 2004, Protein science : a publication of the Protein Society.

[9]  Meital Reches,et al.  Amyloidogenic hexapeptide fragment of medin: homology to functional islet amyloid polypeptide fragments , 2004, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[10]  C. Mirkin,et al.  Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ehud Gazit,et al.  Analysis of the Minimal Amyloid-forming Fragment of the Islet Amyloid Polypeptide , 2001, The Journal of Biological Chemistry.

[12]  Claudio Soto,et al.  β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.

[13]  Susan Jones,et al.  Amyloid-forming peptides from beta2-microglobulin-Insights into the mechanism of fibril formation in vitro. , 2003, Journal of molecular biology.

[14]  E. Gazit,et al.  The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. , 2003, Biochemistry.

[15]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Gazit.  The role of prefibrillar assemblies in the pathogenesis of amyloid diseases , 2004 .

[17]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[18]  Ehud Gazit,et al.  Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism , 2006, Chemical biology & drug design.

[19]  Mark Bowlby,et al.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Klein,et al.  Why Alzheimer’s is a disease of memory: The attack on synapses by Aß oligomers (ADDLs) , 2008, The journal of nutrition, health & aging.

[21]  Sharon Gilead,et al.  Identification and characterization of a novel molecular-recognition and self-assembly domain within the islet amyloid polypeptide. , 2002, Journal of molecular biology.

[22]  Michele Vendruscolo,et al.  Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. , 2005, Journal of molecular biology.

[23]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[24]  Sharon Gilead,et al.  Inhibition of amyloid fibril formation by peptide analogues modified with alpha-aminoisobutyric acid. , 2004, Angewandte Chemie.

[25]  Y. Duan,et al.  The role of Phe in the formation of well-ordered oligomers of amyloidogenic hexapeptide (NFGAIL) observed in molecular dynamics simulations with explicit solvent. , 2005, Biophysical journal.

[26]  S. M. Robinson,et al.  Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease* , 2003, The Journal of Biological Chemistry.

[27]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[28]  K. Yanamandra,et al.  Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. , 2007, Journal of molecular biology.

[29]  Ehud Gazit,et al.  Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. , 2006, Biochemistry.

[30]  Meital Reches,et al.  Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes , 2003, Science.

[31]  R. Leapman,et al.  Amyloid Fibril Formation by Aβ16-22, a Seven-Residue Fragment of the Alzheimer's β-Amyloid Peptide, and Structural Characterization by Solid State NMR† , 2000 .

[32]  Ehud Gazit,et al.  Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. , 2004, Biochemistry.

[33]  Louise C. Serpell,et al.  A simple algorithm locates β‐strands in the amyloid fibril core of α‐synuclein, Aβ, and tau using the amino acid sequence alone , 2007 .

[34]  Dong Jin Kim,et al.  A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. , 2006, ACS chemical biology.